Case Information
*1
MAINE SUPREME JUDICIAL COURT
Reporter of Decisions
Decision:
Docket: Wal-14-533
Argued: October 6, 2015
Decided: February 4, 2016
Panel: SAUFLEY, C.J., and MEAD, GORMAN, JABAR, HJELM, and HUMPHREY, JJ.
STATE OF MAINE
v.
CHRISTOPHER SUDSBURY
PER CURIAM
[¶1] After Christopher Sudsbury sold a single strip of Suboxone to a confidential informant for twenty-five dollars, a jury found him guilty of aggravated trafficking of a schedule W drug (Class A), 17-A M.R.S. § 1105-A(1)(B)(1) (2015), and the court (Waldo County, Alexander, J. ) sentenced him to eight years in prison. [1] The State now concedes that it failed to present evidence—required for purposes of proving the charged Class A crime—that the Suboxone was, in fact, a schedule W drug. [2] See 17-A M.R.S. §§ 1102(1), [3] 1105-A(1)(B)(1) (2015). Thus, we have no choice but to vacate the conviction. [¶2] To prove the charged crime of aggravated trafficking in a schedule W drug, the State had to prove that (1) Sudsbury intentionally or knowingly trafficked in what he knew or believed to be a scheduled drug; (2) the drug sold was “in fact a scheduled drug”; (3) Sudsbury had “one or more prior convictions for any Class A, B or C offense under this chapter or for engaging in substantially similar conduct to that of the Class A, B or C offenses under this chapter in another jurisdiction”; and (4) the trafficked drug was “[a] schedule W drug.” 17-A M.R.S. §§ 1103(1-A), 1105-A(1)(B)(1) (2015). Neither Suboxone itself nor its active ingredient, buprenorphine, is explicitly named as a prohibited scheduled drug in any of the schedules established by the Legislature. See 17-A M.R.S. § 1102 (2015). Thus, proof that Sudsbury sold a strip of Suboxone was insufficient to satisfy the statutory element requiring that the trafficked substance be “in fact a scheduled drug,” see id. § 1103(1-A), or, more particularly, a schedule W drug, see id. § 1105-A(1)(B)(1).
[¶3] To prove that Sudsbury’s conduct fell within the definition of the crime charged, the State was therefore required to present evidence that Suboxone is a drug that falls within one of the listed categories of schedule W drugs, such as “any argues here that the evidence was insufficient to establish that the particular drug, undisputedly identified as Suboxone through its appearance and a chemical analysis, fell within a particular schedule. The Legislature’s recent amendment to the statute defining the drug schedules did not add Suboxone or buprenorphine to any schedule. See P.L. 2015, ch. 330, § 1 (emergency, effective July 12, 2015) (codified at 17-A M.R.S. § 1102 (2015)).
compound, mixture or preparation containing narcotic drugs” that is not listed or described in another schedule. Id. § 1102(1)(I). At trial, however, no evidence was presented to the jury that Suboxone or buprenorphine constituted a narcotic or fell into any other category established in schedule W. See id. § 1102(1).
[¶4] Although the State argues that proof of the sale of the Suboxone strip could support a conviction for the Class C offense of aggravated trafficking of a schedule Z drug, 17-A M.R.S. § 1105-A(1)(B)(6) (2015), neither Suboxone nor its key ingredient buprenorphine is specifically classified as a schedule Z drug, see id. § 1102(4) (identifying substances classified in schedule Z), and again, the State failed to establish that either Suboxone or buprenorphine was a prescription drug “other than those included in schedules W, X or Y” or a nonprescription drug “other than those included in schedules W, X or Y” as designated by the Maine Board of Pharmacy, id. § 1102(4)(A), (C). Thus, contrary to the State’s suggestion, we cannot remand for the entry of a judgment of conviction of trafficking in the lowest schedule of drug because the evidence also fails to identify the substance as falling within that schedule. [5]
[¶5] We also cannot, as the State suggests, remand for a new trial. The
State failed to satisfy its burden of proving an element of the charged crime,
[6]
and
the defendant moved for a judgment of acquittal on that basis to preserve his claim
of error.
See State v. Lane
,
The entry is:
Judgment vacated. Remanded for entry of judgment of acquittal.
On the briefs:
Sean Ociepka, Esq., Belfast, for appellant Christopher Sudsbury Katie R. Hollstrom, Asst. Dist. Atty., District Attorney’s Office, Bath, for appellee State of Maine
Zachary L. Heiden, Esq., ACLU of Maine Foundation, Portland, and Catherine R. Connors, Esq., and Joshua D.
Dunlap, Esq., Pierce Atwood LLP, Portland, for amicus curiae American Civil Liberties Union of Maine Foundation At oral argument:
Sean Ociepka, Esq., for appellant Christopher Sudsbury Katie R. Hollstrom, for appellee State of Maine
Waldo County Superior Court docket number CR-2014-13
F OR C LERK R EFERENCE O NLY
Notes
[1] Because of prior convictions, the sale of the single strip—had it been proven to be a schedule W drug—would have brought Sudsbury within the definition of aggravated trafficking of scheduled drugs. See 17-A M.R.S. § 1105-A(1)(B)(1) (2015). On appeal, Sudsbury has also challenged the legality of his eight-year sentence, but we do not reach that challenge because we vacate the conviction.
[2] Unlike in
State v. Barnard
,
[4] If the schedule of the drug had not been required as an element of the crime but instead served to
increase the sentence for a proved crime beyond a statutory maximum, the jury would similarly be unable
to reach that sentence-increasing finding on the evidentiary record supplied by the State here.
See
U.S.
Const. amends. VI, XIV;
Blakely v. Washington
, 542 U.S. 296, 301 (2004) (“‘Other than the fact of a
prior conviction, any fact that increases the penalty for a crime beyond the prescribed statutory maximum
must be submitted to a jury, and proved beyond a reasonable doubt.’” (quoting
Apprendi v. New Jersey
,
[5] Moreover, the State does not take the position that the drug sold was, in fact, other than a schedule W drug.
[6] Specifically, the State failed to prove that the Suboxone strip was “in fact a scheduled drug,” 17-A M.R.S. § 1103(1-A) (2015), or, more particularly, that it was “[a] schedule W drug,” id. § 1105-A(1)(B)(1).